People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Ypsomed and Sidekick Health are launching an integrated digital health solution to better support people with obesity.

While Lilly's success with GLP-1 drugs is certainly impressive ... multiple of 36. As the chart below illustrates, Lilly's current forward P/E is roughly 40% lower today than it was just a ...

The A1C test measures a person’s average blood glucose or blood sugar levels over the past 3 months. An A1C reading of over 5.6% may be a cause for concern, but this will depend on various ...

Chancellor Rachel Reeves delivered the spring statement on Wednesday, giving an update on the UK economy. In her announcement in the House of Commons, Reeves said that the government's "task is to ...

SAN FRANCISCO - OpenAI is making it easier to edit images in ChatGPT and create visuals for work that include lengthy, legible text, potentially broadening the chatbot’s appeal for businesses ...

Pipeline Highlights and Upcoming Milestones MET-097i rapidly advancing towards Phase 3 MET-097i is a fully biased, monthly, ultra-long acting, potent, subcutaneously injectable GLP-1 receptor ...

Employers are buying into these programs to satisfy worker demand for coverage of GLP-1s such as Wegovy, Zepbound and Saxenda. Others incorporate the PBM offerings into their employee health ...

That these treatments are helping people curb their eating should be no surprise: that is exactly what they are meant to do, by mimicking the satiety hormone GLP-1 (see “How they work”, below).

For pharma R&D, the expected ROI was 5.9% in 2024, up from 2023’s 4.1%. Of note is the role that GLP-1 therapies played in that increase, with the average return dropping to 3.8% when the drug ...